DailyDoctor Archive Specialties Get app
All urology briefings

The edition · Urology

Up to one in nine men start bladder drugs within a year of BPH surgery

A statewide claims study gives procedure-specific benchmarks for new overactive bladder medication after prostate surgery; the 2026 EAU NMIBC update adds checkpoint inhibitors and de-intensification; waterjet ablation works as salvage; and saturation biopsy shows a non-significant gain.

The edition in brief

A Michigan claims study of 11,519 men with no previous overactive bladder medication found that 5.7% to 11% started an anticholinergic or beta-3 agonist between 3 and 12 months after BPH surgery, highest after laser photovaporisation (HR 1.49 vs TURP); prior BPH medication and anticoagulant use raised the risk. The 2026 EAU guideline summary on non-muscle-invasive bladder cancer adds tables on BCG-unresponsive treatment options, a section on adding immune checkpoint inhibitors to BCG for selected BCG-naive high-risk patients, guidance on urinary markers in follow-up, and a pragmatic de-intensification strategy. A multicentre registry of 1,887 men found robotic waterjet ablation after a previous BPH procedure had outcomes and complications similar to first-time treatment. A small Indian comparison of 108 men found targeted saturation biopsy detected clinically significant prostate cancer in 72% versus 57% with standard targeted biopsy, a difference that was not statistically significant.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free